<DOC>
	<DOC>NCT01346410</DOC>
	<brief_summary>This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of unresectable pancreatic cancer.</brief_summary>
	<brief_title>Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer</brief_title>
	<detailed_description>This is a single institution, non-randomized, prospective, phase IV trial of SBRT for unresectable pancreatic cancer. Data collected will include patient demographics, pathology data, tumor stage, SBRT dose fractionation scheme, dose received by adjacent critical normal tissues, tumor recurrence data, and acute and late toxicities. Follow up data will be collected during the patient's standard office visits. The anticipated duration of this study is 5 years.</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Patient age &gt;= 18 years Performance status of 03 Unresectable pancreatic cancer Maximum tumor diameter &lt; 7.5 cm Signed studyspecific consent form Maximum tumor diameter &gt; 7.5 cm Prior radiotherapy to the upper abdomen Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown effects of RT on lactating females Patients with psychiatric or addictive disorder that would preclude obtaining informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>pancreatic cancer</keyword>
</DOC>